These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19956549)
1. Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model. Sachdeva R; Banerjea AC; Malla N; Dubey ML PLoS One; 2009 Dec; 4(12):e7880. PubMed ID: 19956549 [TBL] [Abstract][Full Text] [Related]
2. The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis. Zhang J; He J; Li J; Zhou Q; Chen H; Zheng Z; Chen Q; Chen D; Chen J PLoS One; 2020; 15(3):e0230381. PubMed ID: 32176727 [TBL] [Abstract][Full Text] [Related]
3. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis. Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113 [TBL] [Abstract][Full Text] [Related]
4. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428 [TBL] [Abstract][Full Text] [Related]
5. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Bhowmick S; Ravindran R; Ali N Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029 [TBL] [Abstract][Full Text] [Related]
6. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. Mazumder S; Maji M; Das A; Ali N PLoS One; 2011 Feb; 6(2):e14644. PubMed ID: 21311597 [TBL] [Abstract][Full Text] [Related]
7. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Sukumaran B; Tewary P; Saxena S; Madhubala R Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811 [TBL] [Abstract][Full Text] [Related]
9. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy of DNA vaccine against visceral leishmaniasis in BALB/c mice. Kaur S; Kaur T; Joshi J J Biomed Res; 2016 Jul; 30(4):304-13. PubMed ID: 27533939 [TBL] [Abstract][Full Text] [Related]
11. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Basu R; Bhaumik S; Haldar AK; Naskar K; De T; Dana SK; Walden P; Roy S Infect Immun; 2007 Dec; 75(12):5956-66. PubMed ID: 17908806 [TBL] [Abstract][Full Text] [Related]
12. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Kaur J; Kaur T; Kaur S Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477 [TBL] [Abstract][Full Text] [Related]
13. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine. Seyed N; Taheri T; Vauchy C; Dosset M; Godet Y; Eslamifar A; Sharifi I; Adotevi O; Borg C; Rohrlich PS; Rafati S PLoS One; 2014; 9(10):e108848. PubMed ID: 25310094 [TBL] [Abstract][Full Text] [Related]
15. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564 [TBL] [Abstract][Full Text] [Related]
16. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199 [TBL] [Abstract][Full Text] [Related]
17. Transcriptome Analysis Identifies Immune Markers Related to Visceral Leishmaniasis Establishment in the Experimental Model of BALB/c Mice. Agallou M; Athanasiou E; Kammona O; Tastsoglou S; Hatzigeorgiou AG; Kiparissides C; Karagouni E Front Immunol; 2019; 10():2749. PubMed ID: 31849951 [TBL] [Abstract][Full Text] [Related]
18. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]